Patent ID: RE40387

Claim:
A method of increasing the bioavailability of orally administered epothilones comprising orally administering to a human one or more epothilones compounds of Formula: wherein: G is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, W is O or NR 16 ; X is O; S; CHR 17 ; or H, R 18 ; Y is selected from the group consisting of O; H, H; H, OR 22 ; OR 23 , OR 23 ; NOR 24 ; H, NOR 25 NHOR 25 ; H, HNR 26 R 27 NR 26 R 27 ; NHNR 28 R 29 ; H, NHNR 30 R 31 or CHR 32 , where OR 23 , OR 23 can be a cyclic ketal; B 1 and B 2 are selected from the group consisting of independently H, OR 33 , OCOR 34 , OCONR 35 R 36 , NR 37 R 38 , or NR 39 CONR 40 R 41 ; D is selected from the group consisting of NR 42 R 43 or heterocyclo; R 1 , R 2 , R 3 , R 4 , and R 5 are selected from independently H , or lower alkyl; R 8 , R 9 , R 10 and R 11 are selected from the group consisting of independently H, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, heterocyclo or substituted heterocyclo; R 17 , R 18 , R 22 , and R 23 are selected from the group consisting of independently H, alkyl, and or substituted alkyl; R 24 , R 25 , R 26 , R 28 , R 30 , R 32 , R 33 , R 34 , R 35 , R 36 , R 37 , R 39 , R 40 , R 41 , R 42 , R 51 , R 52 , and R 53 , and R 61 are selected from the group of independently H, alkyl, substituted alkyl, aryl or substituted aryl; R 12 , R 16 , R 27 , R 29 , R 31 , R 38 , and R 43 , are selected from the group consisting of independently H, alkyl, substituted alkyl, substituted aryl, cycloalkyl, heterocyclo, R 51 C═O, R 52 OC═O, R 53 SO 2 , hydroxy, and O-alkyl or O-substituted alkyl , ; or a pharmaceutically acceptable salt, solvate, clathrate, hydrate or prodrug thereof, and orally administering one or more pharmaceutically acceptable acid neutralizing buffers , wherein the bioavailability of the compound is increased with the acid neutralizing buffer compared to that without the acid neutralizing buffer .